171 related articles for article (PubMed ID: 26825737)
1. JAK2 mutation and acute coronary syndrome complicated with stent thrombosis.
Inami T; Okabe M; Matsushita M; Kobayashi N; Inokuchi K; Hata N; Seino Y; Shimizu W
Heart Vessels; 2016 Oct; 31(10):1714-6. PubMed ID: 26825737
[TBL] [Abstract][Full Text] [Related]
2. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
3. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
4. ST-Segment Elevation Myocardial Infarction and Bleeding Complications in JAK2-Negative Polycythemia.
Duran Luciano P; Sabella-Jiménez V
Tex Heart Inst J; 2023 Oct; 50(5):. PubMed ID: 37872693
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes.
Dangas GD; Claessen BE; Mehran R; Xu K; Fahy M; Parise H; Henriques JP; Ohman EM; White HD; Stone GW
JACC Cardiovasc Interv; 2012 Nov; 5(11):1097-105. PubMed ID: 23174632
[TBL] [Abstract][Full Text] [Related]
6. Stent thrombosis in acute coronary syndromes: Patient-related factors and operator-related factors.
Kamenik M; Widimsky P
Anatol J Cardiol; 2020 Oct; 24(4):274-279. PubMed ID: 33001053
[TBL] [Abstract][Full Text] [Related]
7. JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis.
Martínez-Avilés L; Besses C; Alvarez-Larrán A; Cervantes F; Hernández-Boluda JC; Bellosillo B
Haematologica; 2007 Dec; 92(12):1717-8. PubMed ID: 18056003
[TBL] [Abstract][Full Text] [Related]
8. JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.
Yoo JH; Park TS; Maeng HY; Sun YK; Kim YA; Kie JH; Cho EH; Song J; Lee KA; Suh B; Choi JR
Cancer Genet Cytogenet; 2009 Feb; 189(1):43-7. PubMed ID: 19167611
[TBL] [Abstract][Full Text] [Related]
9. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
10. Uncontrolled thrombocytosis in polycythemia vera is a risk for thrombosis, regardless of JAK2(V617F) mutational status.
Ohyashiki K; Akahane D; Gotoh A; Ito Y; Tauchi T; Miyazawa K; Kimura Y; Ohyashiki JH
Leukemia; 2007 Dec; 21(12):2544-5. PubMed ID: 17611562
[No Abstract] [Full Text] [Related]
11. Prior chronic clopidogrel therapy is associated with increased adverse events and early stent thrombosis.
Asher E; Fefer P; Sabbag A; Herscovici R; Regev E; Mazin I; Shlomo N; Zahger D; Atar S; Hammerman H; Polak A; Beigel R; Matetzky S;
Thromb Haemost; 2016 Jan; 115(2):433-8. PubMed ID: 26446379
[TBL] [Abstract][Full Text] [Related]
12. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
13. Cerebellar venous thrombosis mimicking a cerebellar tumor due to polycythemia vera: a case report.
Wen H; Jin D; Chen Y; Cui B; Xiao T
BMC Neurol; 2021 Jun; 21(1):225. PubMed ID: 34134639
[TBL] [Abstract][Full Text] [Related]
14. Outcome of ST-elevation myocardial infarction versus non-ST-elevation acute coronary syndrome treated with titanium-nitride-oxide-coated versus everolimus-eluting stents: insights from the BASE-ACS trial.
Romppanen H; Nammas W; Kervinen K; Mikkelsson J; Pietilä M; Lalmand J; Rivero-Crespo F; Pentikäinen M; Tedjokusumo P; Karjalainen PP
Minerva Cardioangiol; 2013 Apr; 61(2):201-9. PubMed ID: 23492603
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Hematology; 2008 Apr; 13(2):71-6. PubMed ID: 18616871
[TBL] [Abstract][Full Text] [Related]
16. The relationship between factor V Leiden, prothrombin G20210A, and MTHFR mutations and the first major thrombotic episode in polycythemia vera and essential thrombocythemia.
Trifa AP; Cucuianu A; Popp RA; Coadă CA; Costache RM; Militaru MS; Vesa ŞC; Pop IV
Ann Hematol; 2014 Feb; 93(2):203-9. PubMed ID: 23828072
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of Intravascular Ultrasound for Predicting Risk of Intraprocedural Stent Thrombosis.
Morofuji T; Inaba S; Hitsumoto T; Takahashi K; Aisu H; Higashi H; Saito M; Ohshima K; Ikeda S; Hamada M; Sumimoto T
Am J Cardiol; 2016 Mar; 117(6):918-25. PubMed ID: 26822168
[TBL] [Abstract][Full Text] [Related]
18. Polycythemia vera is not initiated by JAK2V617F mutation.
Nussenzveig RH; Swierczek SI; Jelinek J; Gaikwad A; Liu E; Verstovsek S; Prchal JF; Prchal JT
Exp Hematol; 2007 Jan; 35(1):32-8. PubMed ID: 17198871
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the prevalence and prospective clinical impact of the JAK2 V617F mutation in coronary patients.
Muendlein A; Gasser K; Kinz E; Stark N; Leiherer A; Rein P; Saely CH; Grallert H; Peters A; Drexel H; Lang AH
Am J Hematol; 2014 Mar; 89(3):295-301. PubMed ID: 24265174
[TBL] [Abstract][Full Text] [Related]
20. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]